Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue + AS-AQ for Uncomplicated Falciparum Malaria in Children
NCT01407887Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2011
- Primary completion
- Aug 2011
- Countries
- 1
- Sponsor
- Heidelberg University
- Modality
- Small Molecules
- Drugs
- methylene blue
- Conditions
- Malaria
01
Overview
Phase 2, randomised, open-label trial of methylene blue in Malaria (2 arms), sponsored by Heidelberg University. Primary endpoint: P. falciparum gametocyte prevalence at Day 14. Started Aug 2011; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
AS-AQ-MB
Artesunate + Amodiaquine + Methylene Blue
AS-AQ
Artesunate + Amodiaquine
03
Endpoints
Primary
P. falciparum gametocyte prevalence
Secondary
P. falciparum gametocyte prevalence and density
Beyond the preview
Go deeper on NCT01407887.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01407887.